Shanghai, China, 29 March 2022 - MicroPort CardioFlow today announced the annual results of the Company and its subsidiaries for the 12 months ended December 31, 2021. In the Reporting Period, MicroPort CardioFlow recorded revenue of RMB200.8 million, representing a year-on-year growth of 93.2%. In addition to the significant growth in revenue, the gross profit margin also improved drastically by 15.4 percentage points to 59.1%.
Shanghai, China- MicroPort CardioFlow recently announced that the their Alwide® Plus Balloon Catheter has received marketing approval from the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).
MicroPort CardioFlow recently announced that its transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has received marketing approval by the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).
Shanghai, China, 28 December 2021 — MicroPort CardioFlow recently announced that its latest TAVI solution, the new-generation VitaFlow Liberty™ has completed the submission of applications materials for the EU CE certification
MicroPort CardioFlow hosted a symposium for its next-generation transcatheter aortic valve implantation (TAVI) product, the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System, during the 32nd Great Wall International Congress of Cardiology (GW-ICC) and Asia Heart Society Congress. The event brought together experts in the field of structural heart disease to share their experience on the clinical application of VitaFlow Liberty™.
Shanghai, China, 5 November 2021 — MicroPort CardioFlow is set to become the largest shareholder of 4C Medical Technologies, Inc. following the recent completion of a series C preferred shares subscription agreement. As the lead investor of the round, MicroPort CardioFlow will make a strategic investment up to USD 25 million in 4C Medical, and will be granted the exclusive commercial rights to the investigational tricuspid products in China.